IL306088A - Vaccine formulations against coronavirus - Google Patents
Vaccine formulations against coronavirusInfo
- Publication number
- IL306088A IL306088A IL306088A IL30608823A IL306088A IL 306088 A IL306088 A IL 306088A IL 306088 A IL306088 A IL 306088A IL 30608823 A IL30608823 A IL 30608823A IL 306088 A IL306088 A IL 306088A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine formulations
- coronavirus vaccine
- coronavirus
- formulations
- vaccine
- Prior art date
Links
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164487P | 2021-03-22 | 2021-03-22 | |
| US202163176825P | 2021-04-19 | 2021-04-19 | |
| US202163177059P | 2021-04-20 | 2021-04-20 | |
| US202163195986P | 2021-06-02 | 2021-06-02 | |
| US202163280395P | 2021-11-17 | 2021-11-17 | |
| US202163290439P | 2021-12-16 | 2021-12-16 | |
| US202163292196P | 2021-12-21 | 2021-12-21 | |
| US202163293468P | 2021-12-23 | 2021-12-23 | |
| PCT/US2022/020974 WO2022203963A1 (en) | 2021-03-22 | 2022-03-18 | Coronavirus vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL306088A true IL306088A (en) | 2023-11-01 |
Family
ID=83396030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL306088A IL306088A (en) | 2021-03-22 | 2022-03-18 | Vaccine formulations against coronavirus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220332765A1 (https=) |
| EP (1) | EP4313143A4 (https=) |
| JP (1) | JP2024511412A (https=) |
| KR (1) | KR20230160349A (https=) |
| AU (1) | AU2022245141A1 (https=) |
| BR (1) | BR112023019301A2 (https=) |
| CA (1) | CA3213221A1 (https=) |
| IL (1) | IL306088A (https=) |
| MX (1) | MX2023011163A (https=) |
| TW (1) | TW202304955A (https=) |
| WO (1) | WO2022203963A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120227451A (zh) * | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025088585A1 (en) * | 2023-10-25 | 2025-05-01 | Novavax AB | Saponin-based adjuvants and methods of characterizing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968510B1 (en) * | 2013-03-14 | 2019-10-09 | President and Fellows of Harvard College | Nanoparticle-based compositions |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| US20210228707A1 (en) * | 2020-01-28 | 2021-07-29 | Modernatx, Inc. | Coronavirus rna vaccines |
| JP2023512519A (ja) * | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2022
- 2022-03-18 CA CA3213221A patent/CA3213221A1/en active Pending
- 2022-03-18 EP EP22776366.1A patent/EP4313143A4/en active Pending
- 2022-03-18 JP JP2023558130A patent/JP2024511412A/ja active Pending
- 2022-03-18 MX MX2023011163A patent/MX2023011163A/es unknown
- 2022-03-18 AU AU2022245141A patent/AU2022245141A1/en active Pending
- 2022-03-18 IL IL306088A patent/IL306088A/en unknown
- 2022-03-18 WO PCT/US2022/020974 patent/WO2022203963A1/en not_active Ceased
- 2022-03-18 BR BR112023019301A patent/BR112023019301A2/pt unknown
- 2022-03-18 KR KR1020237036140A patent/KR20230160349A/ko active Pending
- 2022-03-22 TW TW111110461A patent/TW202304955A/zh unknown
- 2022-03-22 US US17/700,945 patent/US20220332765A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022245141A9 (en) | 2024-02-22 |
| JP2024511412A (ja) | 2024-03-13 |
| EP4313143A4 (en) | 2025-06-18 |
| BR112023019301A2 (pt) | 2023-12-05 |
| AU2022245141A1 (en) | 2023-10-05 |
| CA3213221A1 (en) | 2022-09-29 |
| KR20230160349A (ko) | 2023-11-23 |
| US20220332765A1 (en) | 2022-10-20 |
| MX2023011163A (es) | 2024-02-27 |
| EP4313143A1 (en) | 2024-02-07 |
| TW202304955A (zh) | 2023-02-01 |
| WO2022203963A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202212336D0 (en) | Coronavirus vaccine formulations | |
| GB2594365B (en) | Coronavirus vaccine | |
| IL314906B2 (en) | Coronavirus vaccine | |
| GB202004974D0 (en) | Coronavirus vaccine | |
| ZA202210641B (en) | Coronavirus vaccine | |
| IL306088A (en) | Vaccine formulations against coronavirus | |
| GB202217951D0 (en) | Coronavirus vaccine | |
| IL297070A (en) | Vaccine against the corona virus | |
| GB2620028B8 (en) | Coronavirus vaccine | |
| GB202207281D0 (en) | Vaccine | |
| HK40117626A (en) | Coronavirus vaccine formulations | |
| HK40105934A (en) | Coronavirus vaccine formulations | |
| HK40075990A (en) | Coronavirus vaccine formulations | |
| GB202016172D0 (en) | Coronavirus vaccine | |
| GB202114318D0 (en) | Coronavirus Vaccines | |
| GB202103214D0 (en) | Coronavirus vaccines | |
| GB202101824D0 (en) | Coronavirus vaccines | |
| GB202015775D0 (en) | Coronavirus vaccines | |
| GB202318080D0 (en) | Coronavirus vaccines | |
| GB202315819D0 (en) | Coronavirus vaccines | |
| GB202315824D0 (en) | Coronavirus vaccines | |
| GB202312403D0 (en) | Coronavirus vaccines | |
| GB202312413D0 (en) | Coronavirus vaccines | |
| GB202305092D0 (en) | Coronavirus vaccines | |
| GB202303150D0 (en) | Coronavirus vaccines |